Neuropharmacokinetics of Eribulin Mesylate in Treating Patients With Primary or Metastatic Brain Tumors

Inclusion Criteria: * Patients must have a Karnofsky performance status of \>= 60 * Brain tumor patient is planning to undergo tumor resection or biopsy for the purpose of differentiating between tumor progression versus treatment-induced effects following radiation therapy and/or chemotherapy \* If a patient has magnetic resonance imaging (MRI) findings consistent with tumor but does not already have a histopathologic diagnosis of cancer, s/he may sign the consent form, but final eligibility for study enrollment will be determined based on results of the frozen section at time of surgery * Patient may have received previous treatment for the brain tumor(s), including radiation (focal brain radiation, whole brain radiation or stereotactic radiosurgery), surgery or chemotherapy * There is no limit to the number of prior chemotherapies * Patients who have previously been treated with eribulin are allowed to participate in the microdialysis portion of the study only * Absolute neutrophil count of \> 1500 cells/mm\^3 * Platelet count \> 100,000 cells/mm\^3 * Total bilirubin \< 2.0 mg/dl * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\]) \< 3 times the institutional upper limit of normal * Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) \< 3 times the institutional upper limit of normal * Serum creatinine \< 1.5 x the institutional upper limit of normal * All subjects must have the ability to understand and the…